Corrigendum: Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs (Frontiers in Neurology, (2018), 9, 10.3389/fneur.2018.01067)

Alessandro Galgani, Caterina Palleria, Luigi Francesco Iannone, Giovambattista De Sarro, Filippo Sean Giorgi, Marta Maschio, Emilio Russo

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original article, there was an error. Themanuscript states that “Apixaban and edoxaban need to be administered twice a day” whereas Edoxaban needs to be administered only once a day as stated in the European Product Information and Summary of Product Characteristics. A correction has been made to the section PHARMACOKINETIC OF DOACS, subsection Direct Factor Xa Inhibitors: “Apixaban, edoxaban and rivaroxaban are selective inhibitors of Xa factor (FXa) by binding its active site both when free or thrombin-bound..

Original languageEnglish
Article number1381
JournalFrontiers in Neurology
Volume10
DOIs
Publication statusPublished - Jan 29 2020

Keywords

  • AEDs
  • antiepileptics
  • CYP
  • dabigatran
  • DOACs
  • interactions
  • P-gp
  • rivaroxaban

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Corrigendum: Pharmacokinetic Interactions of Clinical Interest Between Direct Oral Anticoagulants and Antiepileptic Drugs (Frontiers in Neurology, (2018), 9, 10.3389/fneur.2018.01067)'. Together they form a unique fingerprint.

Cite this